Vanderbilt Center Partners with Saravir Biopharma to Develop Monoclonal Antibodies for Measles Prevention and Treatment

The Vanderbilt Center for Antibody Therapeutics has entered into a strategic agreement with Saravir Biopharma Inc. to develop new human monoclonal antibodies targeting measles infection. This partnership focuses on creating innovative treatments and preventive measures to address the growing global concern over measles outbreaks. The antibodies involved in this initiative were initially identified through advanced research efforts.

The collaboration aims to leverage the expertise of both organizations to combat the resurgence of measles, which remains a significant public health challenge worldwide. By focusing on monoclonal antibody technology, the project seeks to provide a novel approach to treating and preventing the disease. Further details about the timeline or specific development milestones have not been disclosed at this time.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 6, 2026

Author

GOAI